RiddleMC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation, 2010; 122:844–846.
2.
RayKK, SeshasaiSR, WijesuriyaS, SivakumaranR, NethercottS, PreissD, ErqouS, SattarN. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, 2009; 373:1765–1772.
3.
NissenSE, WolskiK. Effect of rosiglitazone on the risk of myocardial infarction, death from cardiovascular causes. N Engl J Med, 2007; 356:2457–2471Erratum in N Engl J Med 2007; 357:100.
4.
NoelRA, BraunDK, PattersonRE, BloomgrenGL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care, 2009; 32:834–838.
5.
BloomgrenG, DoreD, PattersonR, NoelR, BraunD, SeegerJ. Incidence of acute pancreatitis in exenatide initiators compared to other antidiabetic drug initiators: a retrospective, cohort study [abstract 158-OR]American Diabetes Association 69th Scientific Sessions, 2009. professional.diabetes.org/Abstracts_Display.aspx?TYP = 1&CID = 74461. 2010 September 13.
6.
CurrieCJ, PooleCD, GaleEA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia, 2009; 52:1766–1777.
7.
KarterAJ, ParkerMM, MoffetHH, SpenceMM, ChanJ, EttnerSL, SelbyJV. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care, 2006; 29:1757–1763.
8.
FarmerA, WadeA, GoyderE, YudkinP, FrenchD, CravenA, HolmanR, KinmonthAL, NeilA. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ, 2007; 335:132–141.
9.
American Diabetes Association: Standards of medical care in diabetes—2010. Diabetes Care, 2010; 33,Suppl 1:S11–S61Erratum in Diabetes Care 2010;33:692.
10.
ChiassonJL, JosseRG, GomisR, HanefeldM, KarasikA, LaaksoM. STOP-NIDDM Trial Research Group: Acarbose for the prevention of Type 2 diabetes, hypertension, cardiovascular disease in subjects with impaired glucose tolerance: facts, interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia, 2004; 47:969–975discussion 976–977.
11.
RazI, WilsonPW, StrojekK, KowalskaI, BozikovV, GittAK, JermendyG, CampaigneBN, KerrL, MilicevicZ, JacoberSJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care, 2009; 32:381–386.
12.
NAVIGATOR Study Group. HolmanRR, HaffnerSM, McMurrayJJ, BethelMA, HolzhauerB, HuaTA, BelenkovY, BoolellM, BuseJB, BuckleyBM, ChacraAR, ChiangFT, CharbonnelB, ChowCC, DaviesMJ, DeedwaniaP, DiemP, EinhornD, FonsecaV, FulcherGR, GaciongZ, GaztambideS, GilesT, HortonE, IlkovaH, JenssenT, KahnSE, KrumH, LaaksoM, LeiterLA, LevittNS, MareevV, MartinezF, MassonC, MazzoneT, MeaneyE, NestoR, PanC, PragerR, RaptisSA, RuttenGE, SandstroemH, SchaperF, ScheenA, SchmitzO, SinayI, SoskaV, StenderS, TamásG, TognoniG, TuomilehtoJ, VillamilAS, VozárJ, CaliffRM. Effect of nateglinide on the incidence of diabetes, cardiovascular events. N Engl J Med, 2010; 362:1463–1476Erratum in N Engl J Med 2010; 362:1748.
13.
HolmanRR, FarmerAJ, DaviesMJ, LevyJC, DarbyshireJL, KeenanJF. Paul SK; 4-T Study Group: Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med, 2009; 361:1736–1747.
14.
PolonskyW, FisherL, SchikmanC, HinnenD, ParkinC, JelsovskyZ, SchweitzerM, WagnerR. Structured SMBG significantly reduces A1c levels in poorly controlled, non-insulin treated type 2 diabetes: results from the STeP study [abstract 4-LB]American Diabetes Association 70th Scientific Sessions, 2010. professional.diabetes.org/admin/UserFiles/file/SciSessions/2010%20Abstracts/2010%20ADA%20LB%20Abstracts.pdf. 2010 September 13.
15.
MonnierL, MasE, GinetC, MichelF, VillonL, CristolJP, ColetteC. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA, 2006; 295:1681–1687.
16.
MonnierL, ColetteC, MasE, MichelF, CristolJP, BoegnerC, OwensDR. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia, 2010; 53:562–571.
17.
The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes, 1995; 44:968–983.
18.
ZoppiniG, VerlatoG, TargherG, BonoraE, TrombettaM, MuggeoM. Variability of body weight, pulse pressure, glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. Diabetes Metab Res Rev, 2008; 24:624–628.
19.
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet, 1999; 354:617–621.
20.
CavalotF, PetrelliA, TraversaM, BonomoK, FioraE, ContiM, AnfossiG, CostaG, TrovatiM. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab, 2006; 91:813–819.
21.
MonnierL, LapinskiH, ColetteC. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care, 2003; 26:881–885.
22.
Di CarliMF, HachamovitchR. Should we screen for occult coronary artery disease among asymptomatic patients with diabetes?J Am Coll Cardiol, 2005; 45:50–53.
23.
FrancoOH, SteyerbergEW, HuFB, MackenbachJ, NusselderW. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med, 2007; 167:1145–1151.
24.
MannJF, GersteinHC, PogueJ, BoschJ, YusufS. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med, 2001; 134:629–636.
25.
HaffnerSM, LehtoS, RönnemaaT, PyöräläK, LaaksoM. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339:229–234.
26.
NorhammarA, TenerzA, NilssonG, HamstenA, EfendícS, RydénL, MalmbergK. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet, 2002; 359:2140–2144.
27.
AnselminoM, OhrvikJ, MalmbergK, StandlE. Rydén L; Euro Heart Survey Investigators: Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J, 2008; 29:177–184.
28.
GittAK, TowaeF, JuengerC, ZeymerU, ZahnR, SengesJ. Recognition of abnormal glucose metabolism and its impact on treatment in patients with acute myocardial infarction in Germany: results of the SWEETHEART Registry [abstract 5608]Circulation, 2009; 120:S1127.
29.
GaedeP, Lund-AndersenH, ParvingHH, PedersenO. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 2008; 358:580–591.
30.
StrattonIM, AdlerAI, NeilHA, MatthewsDR, ManleySE, CullCA, HaddenD, TurnerRC, HolmanRR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321:405–412.
31.
DuckworthW, AbrairaC, MoritzT, RedaD, EmanueleN, ReavenPD, ZieveFJ, MarksJ, DavisSN, HaywardR, WarrenSR, GoldmanS, McCarrenM, VitekME, HendersonWG. Huang GD; VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009; 360:129–139.
32.
Action to Control Cardiovascular Risk in Diabetes Study Group. GersteinHC, MillerME, ByingtonRP, GoffDCJr, BiggerJT, BuseJB, CushmanWC, GenuthS, Ismail-BeigiF, GrimmRHJr, ProbstfieldJL, Simons-MortonDG, FriedewaldWT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008; 358:2545–2559.
33.
BuseJB, RosenstockJ, SestiG, SchmidtWE, MontanyaE, BrettJH, ZychmaM, BlondeL. LEAD-6 Study Group: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)Lancet, 2009; 374:39–47.
34.
PratleyRE, NauckM, BaileyT, MontanyaE, CuddihyR, FilettiS, ThomsenAB, SøndergaardRE, DavisM. 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet, 2010; 375:1447–1456.
35.
CourrègesJP, VilsbøllT, ZdravkovicM, Le-ThiT, KrarupT, SchmitzO, VerhoevenR, BugáñováI, MadsbadS. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med, 2008; 25:1129–1131.
36.
VilsbøllT, ZdravkovicM, Le-ThiT, KrarupT, SchmitzO, CourrègesJP, VerhoevenR, BugánováI, MadsbadS. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care, 2007; 30:1608–1610.
37.
NikolaidisLA, MankadS, SokosGG, MiskeG, ShahA, ElahiD, ShannonRP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 2004; 109:962–965.
38.
Noyan-AshrafMH, MomenMA, BanK, SadiAM, ZhouYQ, RiaziAM, BaggioLL, HenkelmanRM, HusainM, DruckerDJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes, 2009; 58:975–983.
39.
YadavD, LowenfelsAB. Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas, 2006; 33:323–330Erratum in Pancreas 2007;34:174.
PanCQ, BuxtonJM, YungSL, TomI, YangL, ChenH, MacDougallM, BellA, ClausTH, ClairmontKB, WhelanJP. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J Biol Chem, 2006; 281:12506–12515.
42.
AicherT, AndersonD, BoydS, ChicarelliM, CondroskiK, DeWolfWJr, FellJB, FischerJ, FrankM, GalbraithS, GarreyR, GunawardanaI, HinklinR, HirschJ, LeeP, NeitzelN, PrattS, SinghA, ThomasL, TurnerT, VoegtliW, WallaceE, WilliamsL. Discovery of ARRY-588, a novel glucokinase activator with potent glucose lowering activity in animal models of type 2 diabetes mellitus. ARRAY Biopharma Inc.www.arraybiopharma.com/_documents/Publication/PubAttachment288.pdf. 2010 September 13.
43.
RosenstockJ, BanarerS, FonsecaVA, InzucchiSE, SunW, YaoW, HollisG, FloresR, LevyR, WilliamsWV, SecklJR, HuberR. INCB13739-202 Principal Investigators. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care, 2010; 33:1516–1522.
44.
ManchemVP, GoldfineID, KohanskiRA, CristobalCP, LumRT, SchowSR, ShiS, SpevakWR, LabordeE, ToavsDK, VillarHO, WickMM, KozlowskiMR. A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo. Diabetes, 2001; 50:824–830.
45.
BaileyCJ, GrossJL, PietersA, BastienA, ListJF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet, 2010; 375:2223–2233.
46.
ShashajB, BusettoE, SulliN. Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII)Diabet Med, 2008; 25:1036–1042.
47.
FreckmannG, ZisserH, PleusS, HaugC, JendrikeN, ParkinC, SchweitzerM, WagnerR. Clinical performance of three bolus calculators in twenty-four subjects with type 1 diabetes mellitus: a head-to-head comparison [abstract 535-P]American Diabetes Association 70th Scientific Sessions, 2010. professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=79483. 2010 September 13.
